Skip to Main Content

In disappointing news for Pfizer, a study found that its controversial Chantix pill for quitting smoking failed to show any benefit over nicotine patches and lozenges among people trying to kick their habit.

Although the study did not question the effectiveness of the product, the findings may represent another hurdle in the quest to transform Chantix into a blockbuster seller. Ever since it was approved a decade ago, Chantix has been dogged by safety concerns, lawsuits, and languishing sales.


The study, which was published in the Journal of the American Medical Association, compared three approaches to quitting smoking in which 1,086 patients either used a nicotine patch, the Chantix pill, or a combination of a patch and nicotine lozenge.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.